Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
The World Health Organization (WHO) has honored the individuals, government agencies, researchers and organizations from…
On 31st May 2026 Veteran playback singer Suman Kalyanpur passed away in Mumbai. She was…
Indian Badminton duo Satwiksairaj Rankireddy and Chirag Shetty have won the Singapore Open 2026 men's…
June is the sixth month of the year and consists of 30 days. The month…
The recent forest fire incident in Kasauli, Himachal Pradesh highlighted the critical role of aerial…
General NS Raja Subramani officially took charge as the India's next Chief of Defense Staff…